Von Stackelberg 2011.

Methods	Method of randomisation not clear
Participants	420 children with relapsed acute lymphoblastic leukaemia (aged 18 years or less)
Interventions	Unclear from the current information: patients might have received anthracyclines in both treatment groups (N=210 in each group) and if not, there might be a difference in treatment other than anthracyclines between study groups
Outcomes	No difference in 5 year EFS, 5 year OS and treatent related mortality between the treatment groups, significantly less relapses and mucositis, but significantly more hematological toxicity in the patients who definitely received anthracyclines (idarubicin)
Notes	This study has not been published in full text (October 2013), but has been presented at the ASH conference 2011 It is not yet clear if this study is eligible for inclusion in this review

EFS: event‐free survival; OS: overall survival; SIOP: International Society for Paediatric Oncology; ASH: America Society of Hematology